Bioforce elects not to participate in NAD inquiry
NEW YORK The National Advertising Division of the Council of Better Business Bureaus on Monday referred advertising from Bioforce USA for Sanhelios Curbita Bladder Caps to the Federal Trade Association and the Food and Drug Administration following the company’s refusal to participate in an NAD proceeding.
Claims made by Bioforce that were at issue in print and internet advertising included:
- “Sanhelios found that the oil derived from a special species of pumpkinseed, Curbita provides a unique ability to enhance bladder function for men and women.”
- “Pumpkin Seed Oil supports the entire system of bladder muscles.”
- “This capsule holds the secret for strengthening the bladder.”
- “Curbita Bladder Caps has the unique ability to enhance bladder function for men and women”
- “It helps strengthen bladder muscles while supporting normal emptying of the bladder through the calming effect of this high dosage pumpkin power capsule.”
- “It supports normal emptying of the bladder because Curbita has a calming and harmonizing effect on the function of bladder muscles. This leads to a strengthening of the functional-urinary system for mean and women.”
- “Sanhelios found that high dosages of Curbita, pumpkins, have a unique ability to enhance bladder function, leading to a strengthening of the bladder muscles as well as the functional-urinary system.”
- “For a strong , healthy bladder, try Curbita”
The advertiser, in response to NAD’s inquiry, advised NAD that it had elected not to participate in the NAD review proceeding because the challenge was initiated by the Council of Responsible Nutrition. The advertiser contended that because CRN has funded the expansion of NAD’s review of dietary-supplement advertising, the advertiser believed the challenge to be improper.
NAD, in its decision, noted that it was disappointed by the advertiser’s decision not to provide a substantive response, especially in light of the strong health-related claims being made in the advertising.
Next, LaValle announce positive results from Seditol study
SALINAS, Calif. Next Pharmaceuticals and The LaValle Metabolic Institute last week announced the results of a clinical study on Seditol, concluding that the natural formulation provides relaxation, promotes restful sleep and helps reduce fatigue due to lack of sleep with minimal side effects.
“I believe that Seditol is a great alternative for people who are interested in a natural approach to managing sleeplessness,” stated Charles Kosmont, chief executive officer and president of Next Pharmaceuticals. “Exhausted Americans filled almost 50 million prescriptions for sleeping pills last year.”
The open-label, single-center trial of 773 people was completed by the LaValle Metabolic Institute in Cincinnati. Of those, 718 reported that Seditol helped them relax; 680 reported Seditol helped them have a restful night’s sleep; and 696 reported Seditol helped reduce fatigue due to lack of sleep.
Warburg Pincus completes B&L acquisition
ROCHESTER, N.Y. Bausch & Lomb and Warburg Pincus on Friday announced that Warburg Pincus has completed the acquisition of B&L for a total purchase price of approximately $4.5 billion, including the assumption of approximately $830 million in debt.
The company’s stock ceased trading on the New York Stock Exchange and was delisted by close of market Friday, the company announced.
“With a strong and supportive partner in Warburg Pincus, we are well-positioned to create new opportunities for Bausch & Lomb and advance our leadership in the eye health industry,” stated Ronald Zarrella, chairman and chief executive officer of B&L. “Our customers will continue to receive high levels of service, product quality and innovation, and our commitment to serving their needs remains steadfast.”